Core Viewpoint - The company, Zhixiang Jintai, has entered into exclusive cooperation agreements with subsidiaries of Kangzhe Pharmaceutical Holdings and RXILIENT Medical for two monoclonal antibody injections, GR2001 and GR1801, which will provide significant financial benefits and exclusive commercialization rights in various regions [1][2]. Group 1: GR2001 Injection Agreement - Zhixiang Jintai will receive upfront payments and milestone payments totaling up to approximately 260 million RMB for the GR2001 injection [1] - Kangzhe Pharmaceutical will obtain exclusive commercialization rights for GR2001 in mainland China, while RXILIENT will have exclusive licensing rights for the Asia-Pacific region and the Middle East and North Africa [1] - The company will also earn revenue based on net sales adjustments from regions outside mainland China and will pay promotional service fees to Kangzhe Pharmaceutical based on sales revenue in mainland China [1] Group 2: GR1801 Injection Agreement - Zhixiang Jintai will receive upfront payments and milestone payments totaling up to approximately 250 million RMB for the GR1801 injection [2] - Kangzhe Pharmaceutical will gain exclusive commercialization rights for GR1801 in mainland China, while RXILIENT will have exclusive licensing rights for the Asia-Pacific region and the Middle East and North Africa [2] - Similar to the GR2001 agreement, the company will earn revenue based on net sales adjustments from regions outside mainland China and will pay promotional service fees to Kangzhe Pharmaceutical based on sales revenue in mainland China [2]